Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

23 Jul 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ADMA Biologics Inc (ADMA-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

24 Jul 2016 Thomson Reuters Stock Report 12 $25.00

ValuEngine Rating and Forecast Report for ADMA

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

24 Jul 2016 ValuEngine, Inc. 11 $25.00

Wright Investors Service Comprehensive Report for Adma Biologics Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

13 Jul 2016 Wright Reports 60 $75.00

ADMA BIOLOGICS INC (ADMA=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

02 Jul 2016 Pechala's Reports 2 $25.00

Laidlaw: ADMA: 1Q16: With cash shortfall concerns behind It, likely RI-002 in RSV prevention of PIDD approval is fast approaching

ADMA recently reported 1Q16 results with a net loss of ($4.6MM) vs. Laidlaw ($4.8MM) and the Street ($4.0MM) estimates. Net l...

16 May 2016 Laidlaw & Company 8 $25.00

Thomson Reuters Stock Report - ADMA Biologics Inc (ADMA-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 12 $25.00

ADMA: 4Q15: All eyes are on potential approval in 3Q16 for RI-002 in RSV prevention of PIDD patients

Yesterday, ADMA reported 4Q15 results with a net loss of ($4.6MM), net loss per share of ($0.44), and ~$16.8MM cash, sufficie...

24 Mar 2016 Laidlaw & Company 8 $25.00

ADMA BIOLOGICS INC (ADMA=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

14 Nov 2015 Pechala's Reports 2 $25.00

ADMA: 3Q15: Potential approval in 3Q16 for RI-002 in RSV prevention in PIDD patients

Yesterday, ADMA reported 3Q15 results with a net loss of ($5.1MM) vs. Laidlaw ($4.9MM) and the Street ($4.2MM) estimates. N...

11 Nov 2015 Laidlaw & Company 8 $25.00